GLP-1 RA prescriptions were associated with greater protection against uveitis compared with the cohorts taking metformin and insulin. (HealthDay News) — Glucagon-like peptide 1 receptor agonists (GLP ...

GLP-1 therapy may lower CKD dementia risk and Alzheimer’s incidence in diabetic patients. Explore the latest evidence and clinical implications.

A systematic review and meta-analysis published in Hepatology has revealed that GLP-1 receptor agonists and SGLT2 inhibitors are associated with lower risks of liver-related events and hepatocellular ...

The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, according to a study published online Feb. 9 in the Journal of the ...

An increased risk for nonarteritic anterior ischemic optic neuropathy was seen in association with 2 GLP-1 RAs (hazard ratios, 1.39 and 1.25 for semaglutide and liraglutide, respectively). HealthDay ...

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.

In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week ...

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...

GLP-1 RAs linked to lower risk among those with type 2 diabetes and without diabetes; greater protection seen versus metformin, insulin. (HealthDay News) — Glucagon-like peptide 1 receptor agonists ...

Association seen in seniors with type 2 diabetes; greater associations seen for semaglutide and liraglutide. (HealthDay News) — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor ...